Enlicitide Tablets 20 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 20 mg

Reference Brands: Lipfendra

Category: Heart Disorder

Enlicitide (Lipfendra, Merck/MSD) is the first PCSK9 inhibitor taken as a tablet, used to lower LDL cholesterol. The US FDA approved it in July 2026. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.

Product Description:

Enlicitide decanoate blocks PCSK9, a protein that makes the liver destroy its own LDL receptors. With PCSK9 blocked, the liver keeps more receptors and clears more LDL ("bad") cholesterol from the blood. Until now this mechanism was only available as injections, either antibodies (evolocumab, alirocumab) or the siRNA inclisiran. Enlicitide is a macrocyclic peptide designed to be absorbed from the gut, so it is taken as a 20 mg tablet once a day.

The US FDA approved enlicitide as Lipfendra in July 2026 to lower LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, usually on top of a statin. It gives people who need more LDL lowering an oral option instead of regular injections.

Sourcing and licensing notes. Enlicitide is patented and made only by Merck & Co (MSD outside the US and Canada); there is no generic. We confirm registration status for each destination before quoting, handle enquiries for authorised supply of Lipfendra where it can lawfully be imported, and we connect developers and licensees interested in the oral PCSK9 class ahead of patent expiry.